-
公开(公告)号：US20190127387A1
公开(公告)日：2019-05-02
申请号：US16091541
申请日：2017-04-06
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Yangbing Li , Jiuling Yang , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Rohan Rej , Xin Han
IPC: C07D487/10 , C07D401/04 , C07D401/14 , C07D417/14 , A61P35/00
Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
-
公开(公告)号：US10759808B2
公开(公告)日：2020-09-01
申请号：US16091544
申请日：2017-04-06
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Yangbing Li , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Chong Qin , Yang Hu , Weiguo Xiang , Rohan Rej , Jiuling Yang , Xin Han , Longchuan Bai , Chao-Yie Yang
IPC: C07D401/04 , C07D487/10 , C07D401/14 , C07D487/04 , C07D495/14
Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
-
公开(公告)号：US11192898B2
公开(公告)日：2021-12-07
申请号：US16091541
申请日：2017-04-06
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Yangbing Li , Jiuling Yang , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Rohan Rej , Xin Han
IPC: C07D487/10 , C07D401/04 , A61P35/00 , C07D401/14 , C07D417/14
Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
-
公开(公告)号：US20210130401A1
公开(公告)日：2021-05-06
申请号：US16605057
申请日：2018-05-15
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Yangbing Li , Hacer Karatas , Liu Liu , Jeanne Stuckey , Yali Dou , Liyue Huang , Atsunori Kaneshige
Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.
-
Patent Agency Ranking
公开(公告)号：US20190119289A1
公开(公告)日：2019-04-25
申请号：US16091544
申请日：2017-04-06
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Yangbing Li , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Chong Qin , Yang Hu , Weiguo Xiang , Rohan Rej , Jiuling Yang , Xin Han , Longchuan Bai , Chao-Yie Yang
IPC: C07D487/10 , C07D401/04 , C07D401/14 , C07D495/14 , C07D487/04
Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
-
公开(公告)号：US11046703B2
公开(公告)日：2021-06-29
申请号：US16594344
申请日：2019-10-07
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Angelo Aguilar , Yangbing Li , Jiuling Yang , Donna McEachern
IPC: C07D487/10
Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
-
公开(公告)号：US20210002289A1
公开(公告)日：2021-01-07
申请号：US17007191
申请日：2020-08-31
Applicant: The Regents of the University of Michigan
Inventor： Yangbing Li , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Chong Qin , Yang Hu , Weiguo Xiang , Rohan Rej , Jiuling Yang , Xin Han , Longchuan Bai , Chao-Yie Yang
IPC: C07D487/10 , C07D401/04 , C07D401/14 , C07D487/04 , C07D495/14
Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
-
公开(公告)号：US20220411432A1
公开(公告)日：2022-12-29
申请号：US17462355
申请日：2021-08-31
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Yangbing Li , Jiuling Yang , Angelo Aguilar , Bing Zhou , Jiantao Hu , Fuming Xu , Rohan Rej , Xin Han
IPC: C07D487/10 , C07D401/04 , A61P35/00 , C07D401/14 , C07D417/14
Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
-
公开(公告)号：US20210309666A1
公开(公告)日：2021-10-07
申请号：US17342974
申请日：2021-06-09
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Angelo Aguilar , Yangbing Li , Jiuling Yang , Donna McEachern
IPC: C07D487/10
Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.021 seconds)
